Tang Zhe, Kang Muxing, Zhang Bo, Chen Jianke, Fang Heqing, Ye Qin, Jiang Biao, Wu Yulian
Department of Surgery, 2 Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou - China.
Department of Ultrasound, 2 Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou - China.
Tumori. 2017 May 12;103(3):286-291. doi: 10.5301/tj.5000585. Epub 2016 Dec 26.
Hepatocellular carcinoma (HCC) is a leading cause of death worldwide. Among the surgical and nonsurgical treatments available, radiofrequency ablation (RFA) and sorafenib have been shown to have efficacy. There is little evidence whether combination of these therapies would have additional benefits.
In a mouse model of HCC, effects of sorafenib were determined by tumor size, RFA-induced necrosis area (triphenyltetrazolium chloride staining), microvascular density (MVD; 4',6-diamidino-2-phenylindole and anti-CD31 antibody staining), and tumor perfusion (magnetic resonance imaging).
The RFA-induced necrosis area was 80.98 ± 9.14 and 69.49 ± 7.46 mm2 in mice administered 80 and 40 mg/kg sorafenib, respectively, but only 57.29 ± 3.39 mm2 in controls. Sorafenib also reduced tumor volume and enhanced RFA-induced tumor destruction in a dose-dependent manner, and reduced both MVD and tumor perfusion.
The results of our study suggest a potential role for combining RFA with sorafenib for treatment of HCC. Sorafenib could enhance RFA efficiency, possibly through its angiogenesis suppressive effects.
肝细胞癌（HCC）是全球主要的死亡原因之一。在现有的手术和非手术治疗方法中，射频消融（RFA）和索拉非尼已被证明具有疗效。几乎没有证据表明这些疗法联合使用是否会带来额外的益处。
在肝癌小鼠模型中，通过肿瘤大小、RFA诱导的坏死面积（氯化三苯基四氮唑染色）、微血管密度（MVD；4',6-二脒基-2-苯基吲哚和抗CD31抗体染色）以及肿瘤灌注（磁共振成像）来确定索拉非尼的作用。
分别给予80和40mg/kg索拉非尼的小鼠，RFA诱导的坏死面积分别为80.98±9.14和69.49±7.46mm²，而对照组仅为57.29±3.39mm²。索拉非尼还以剂量依赖的方式减小肿瘤体积并增强RFA诱导的肿瘤破坏，并降低MVD和肿瘤灌注。
我们的研究结果表明RFA与索拉非尼联合治疗HCC具有潜在作用。索拉非尼可能通过其抑制血管生成的作用提高RFA效率。
